Haematologica (Jan 2020)
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
- Bhagirathbhai Dholaria,
- Bipin N. Savani,
- Myriam Labopin,
- Leo Luznik,
- Annalisa Ruggeri,
- Stephan Mielke,
- Monzr M. Al Malki,
- Piyanuch Kongtim,
- Ephraim Fuchs,
- Xiao-Jun Huang,
- Franco Locatelli,
- Franco Aversa,
- Luca Castagna,
- Andrea Bacigalupo,
- Massimo Martelli,
- Didier Blaise,
- Patrick Ben Soussan,
- Yolande Arnault,
- Rupert Handgretinger,
- Denis-Claude Roy,
- Paul O’Donnell,
- Asad Bashey,
- Scott Solomon,
- Rizwan Romee,
- Philippe Lewalle,
- Jorge Gayoso,
- Michael Maschan,
- Hillard M. Lazarus,
- Karen Ballen,
- Sebastian Giebel,
- Frederic Baron,
- Fabio Ciceri,
- Jordi Esteve,
- Norbert-Claude Gorin,
- Alexandros Spyridonidis,
- Christoph Schmid,
- Stefan O. Ciurea,
- Arnon Nagler,
- Mohamad Mohty
Affiliations
- Bhagirathbhai Dholaria
- Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
- Bipin N. Savani
- Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
- Myriam Labopin
- Department of Haematology and EBMT Paris study office / CEREST-TC, Saint Antoine Hospital, Paris, France
- Leo Luznik
- Department of Oncology Hematologic Malignancies, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Annalisa Ruggeri
- Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
- Stephan Mielke
- Department of Laboratory Medicine, CAST, Karolinska Institutet and University Hospital, Stockholm, Sweden
- Monzr M. Al Malki
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA
- Piyanuch Kongtim
- Stem Cell Transplant and Cellular Therapy, Thammasat University, Pathumthani, Thailand
- Ephraim Fuchs
- Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
- Xiao-Jun Huang
- Peking University People’s Hospital, Peking University Institute of Hematology, Beijing China
- Franco Locatelli
- Department of Pediatric Hematology/Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Sapienza, University of Rome, Italy
- Franco Aversa
- Department of Medicine and Surgery, University of Parma, Parma, Italy
- Luca Castagna
- Instituto Clinico Humanitas, Rozzano Milano, Italy
- Andrea Bacigalupo
- Fondazione Policlinico Universitario Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
- Massimo Martelli
- University of Perugia, Sant’Andrea Delle Fratte, Perugia Italy
- Didier Blaise
- Department of Hematology, Institut Paoli Calmettes, Marseille France
- Patrick Ben Soussan
- Department of Clinical Psychology, Paoli-Calmettes Institute, Marseille, France
- Yolande Arnault
- Institut Paoli-Calmette, département de psychologie clinique, Marseille, France
- Rupert Handgretinger
- Department of Hematology and Oncology, University Children’s Hospital Tübingen, Tübingen Germany
- Denis-Claude Roy
- Division of Hematology and Medical Oncology, Hospital Maisonneuve-Rosemont, Montreal, QC, Canada
- Paul O’Donnell
- Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- Asad Bashey
- Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA
- Scott Solomon
- Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA
- Rizwan Romee
- Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Philippe Lewalle
- Hematology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
- Jorge Gayoso
- HGU Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
- Michael Maschan
- Oncology and immunology, Dmitriy Rogachev National Medical Center of pediatric hematology, Moscow, Russia
- Hillard M. Lazarus
- Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH, USA
- Karen Ballen
- Division of hematology/oncology, University of Virginia Health System, Charlottesville, VA, USA
- Sebastian Giebel
- Dept. of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Institute - Oncology Center, Gliwice Branch, Gliwice, Poland
- Frederic Baron
- Laboratory of Hematology, University of Liège, Liège, Belgium
- Fabio Ciceri
- Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano Italy
- Jordi Esteve
- Hematology department, Hospital Clínic de Barcelona, Barcelona Spain
- Norbert-Claude Gorin
- Service d’hématologie et thérapie cellulaire Centre international greffes APHP-EBMT-INCa Hospital, Saint Antoine Hospital, Paris France
- Alexandros Spyridonidis
- Bone Marrow Transplantation Unit and CBMDP Donor Center, University Hospital of Patras, Patras, Greece
- Christoph Schmid
- Department of Hematology and Oncology, Klinikum Augsburg, Augsburg, Germany
- Stefan O. Ciurea
- Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Arnon Nagler
- Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel and EBMT ALWP office, Saint Antoine Hospital, Paris, France
- Mohamad Mohty
- Service d’Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorobonne University, and INSERM UMRs 938, Paris, France
- DOI
- https://doi.org/10.3324/haematol.2019.219790
- Journal volume & issue
-
Vol. 105,
no. 1
Abstract
Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remissions in a subset of patients. With the increased use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.
